Compare TWIN & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | CCCC |
|---|---|---|
| Founded | 1918 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 240.3M |
| IPO Year | N/A | 2020 |
| Metric | TWIN | CCCC |
|---|---|---|
| Price | $18.84 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $7.25 |
| AVG Volume (30 Days) | 34.0K | ★ 1.7M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $347,837,000.00 | $30,108,000.00 |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $782.37 | ★ N/A |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $6.16 | $1.09 |
| 52 Week High | $19.33 | $4.03 |
| Indicator | TWIN | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 68.79 | 51.91 |
| Support Level | $16.79 | $2.02 |
| Resistance Level | $18.96 | $2.47 |
| Average True Range (ATR) | 0.73 | 0.15 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 93.29 | 63.33 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.